C A Meyers

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Neurocognitive effects of therapeutic irradiation for base of skull tumors
    C A Meyers
    Department of Neuro Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 46:51-5. 2000
  2. ncbi Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial
    Christina A Meyers
    Department of Neuro Oncology, Unit 431, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Clin Oncol 22:157-65. 2004
  3. ncbi Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome
    Christina A Meyers
    Department of Neurooncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:788-93. 2005
  4. ncbi Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression
    Christina A Meyers
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Neuro Oncol 5:89-95. 2003
  5. ncbi Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors
    Christina A Meyers
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1305-9. 2006
  6. ncbi How chemotherapy damages the central nervous system
    Christina A Meyers
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 431, Houston, TX 77030, USA
    J Biol 7:11. 2008
  7. ncbi Cognitive function as a predictor of survival in patients with recurrent malignant glioma
    C A Meyers
    Departments of Neuro Oncology and Biomathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:646-50. 2000
  8. ncbi The opioid mechanism of interferon-alpha action
    B T Ho
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston 77030
    Anticancer Drugs 5:90-4. 1994
  9. ncbi Methylphenidate therapy improves cognition, mood, and function of brain tumor patients
    C A Meyers
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2522-7. 1998
  10. ncbi 'Chemobrain' in breast carcinoma?: a prologue
    Jeffrey S Wefel
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:466-75. 2004

Detail Information

Publications46

  1. ncbi Neurocognitive effects of therapeutic irradiation for base of skull tumors
    C A Meyers
    Department of Neuro Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 46:51-5. 2000
    ..To determine whether radiation therapy delivered to the paranasal sinuses causes any long-term impairment in neurocognitive function as a result of incidental brain irradiation...
  2. ncbi Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial
    Christina A Meyers
    Department of Neuro Oncology, Unit 431, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Clin Oncol 22:157-65. 2004
    ....
  3. ncbi Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome
    Christina A Meyers
    Department of Neurooncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:788-93. 2005
    ..The objective of the current study was to assess the correlations between cognitive function, fatigue, quality of life, and circulating cytokine levels in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)...
  4. ncbi Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression
    Christina A Meyers
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Neuro Oncol 5:89-95. 2003
    ..New drugs that slow the cognitive decline of brain tumor patients may be of clinical benefit regardless of the impact on overall survival...
  5. ncbi Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors
    Christina A Meyers
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1305-9. 2006
    ..Including this aspect of patient evaluation in addition to survival and time to tumor progression will yield better risk-versus-benefit assessments as well as provide a basis for improving interventions...
  6. ncbi How chemotherapy damages the central nervous system
    Christina A Meyers
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 431, Houston, TX 77030, USA
    J Biol 7:11. 2008
    ..A new study shows that short-term chemotherapy causes not only acute injury to progenitor cells, but also delayed damage to myelin...
  7. ncbi Cognitive function as a predictor of survival in patients with recurrent malignant glioma
    C A Meyers
    Departments of Neuro Oncology and Biomathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:646-50. 2000
    ..To determine the contribution of cognitive function in predicting the survival of patients with recurrent malignant brain tumors...
  8. ncbi The opioid mechanism of interferon-alpha action
    B T Ho
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston 77030
    Anticancer Drugs 5:90-4. 1994
    ..d-Amphetamine (0.8 mg/kg) was shown to potentiate both EKC (0.1 mg/kg) and IFN-alpha (1 x 10(6) U/kg). The present study confirms our previously proposed opioid-mediated dopaminergic mechanism of IFN-alpha...
  9. ncbi Methylphenidate therapy improves cognition, mood, and function of brain tumor patients
    C A Meyers
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2522-7. 1998
    ..We sought to determine whether methylphenidate treatment would improve these patients' neurobehavioral functioning despite their expected neurologic deterioration...
  10. ncbi 'Chemobrain' in breast carcinoma?: a prologue
    Jeffrey S Wefel
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:466-75. 2004
    ....
  11. ncbi Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation
    David R Grosshans
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:589-95. 2008
    ..Neuropsychologic testing was prospectively conducted before and after PCI to evaluate its effects on cognitive function in patients with SCLC...
  12. ncbi Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target
    J S Wefel
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX 77030 4009, USA
    Br J Cancer 90:1691-6. 2004
    ..The following review provides a summary of the current state of knowledge and highlights future directions...
  13. ncbi Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas
    V A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:58-66. 2002
    ..To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with i.v. carboplatin for patients with previously untreated anaplastic gliomas...
  14. ncbi Chemotherapy and cognition: effects, potential mechanisms, and management
    Anne E Kayl
    The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 1402, USA
    Am J Ther 13:362-9. 2006
    ..Once these groups are identified and the mechanisms underlying the decline are elucidated, attention may be turned to the development of treatments that may optimize cognitive function and improve patient quality of life...
  15. ncbi The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial
    Jeffrey S Wefel
    Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2292-9. 2004
    ..Identification of mechanisms associated with cognitive dysfunction and of risk factors contributing to subgroup vulnerability is necessary...
  16. ncbi Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:308-14. 2004
    ..The present study was designed to determine the toxicity and pharmacokinetics of carboplatin in combination with TNP-470 in comparison with the doublet regimen of paclitaxel and carboplatin in patients with solid tumors...
  17. ncbi Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
    Eric L Chang
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 10:1037-44. 2009
    ..We proposed that the learning and memory functions of patients who undergo SRS plus WBRT are worse than those of patients who undergo SRS alone. We did a randomised controlled trial to test our prediction...
  18. ncbi Neurocognitive and quality of life measures in patients with metastatic brain disease
    Mariana E Witgert
    Section of Neuropsychology, Department of Neuro Oncology, Unit 431, University of Texas MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Neurosurg Clin N Am 22:79-85, vii. 2011
    ....
  19. ncbi Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients
    Anne E Kayl
    University of Texas, MD Anderson Cancer Center, Houston, Texas 77030 1402, USA
    Curr Opin Obstet Gynecol 18:24-8. 2006
    ..In this review, we will highlight recent research on side-effects of chemotherapy and the quality-of-life concerns of women with ovarian and breast cancer...
  20. ncbi Neuropsychological sequelae of non-central nervous system cancer and cancer therapy
    Jeffrey S Wefel
    Department of Neuro Oncology, Section of Neuropsychology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX 77030 4009, USA
    Neuropsychol Rev 18:121-31. 2008
    ....
  21. ncbi Cognitive impairment in men with testicular cancer prior to adjuvant therapy
    Jeffrey S Wefel
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:190-6. 2011
    ..This study characterized cognitive dysfunction before adjuvant chemotherapy in a sample of men diagnosed with nonseminomatous germ cell tumors (NSGCT) of the testis...
  22. ncbi Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer
    Jeffrey S Wefel
    The University of Texas M D Anderson Cancer Center, Section of Neuropsychology, Department of Neuro Oncology, Houston, Texas 77230 1402, USA
    Cancer 116:3348-56. 2010
    ....
  23. ncbi Does brain tumor histology influence cognitive function?
    Anne E Kayl
    The University of Texas MD Anderson Cancer Center, Department of Neuro Oncology, Houston, TX 77030, USA
    Neuro Oncol 5:255-60. 2003
    ..We conclude that tumor histology is not clearly predictive of cognitive performance in adults with AA and GBM...
  24. ncbi Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004
    ..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas...
  25. ncbi Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms
    Charles S Cleeland
    Department of Symptom Research, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:2919-25. 2003
    ..These symptoms include pain, wasting, fatigue, cognitive impairment, anxiety, and depression, many of which co-occur. There is growing recognition that at least some of these symptoms may share common biologic mechanisms...
  26. ncbi A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone
    Eric L Chang
    Department of Radiation Oncology, The University of Texas, Houston, Texas 77030, USA
    Neurosurgery 60:277-83; discussion 283-4. 2007
    ..This report provides data from a pilot study in which neurocognitive function (NCF) was prospectively measured for patients with one to three newly diagnosed brain metastases treated with initial SRS alone...
  27. ncbi Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:4440-7. 2002
    ..TNP-470 was administered with paclitaxel to adults with solid tumors to define the safety and optimal dose of the combination regimen and to assess pharmacokinetic interactions...
  28. ncbi Neurobehavioral functioning of adults with pituitary disease
    C A Meyers
    University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Psychother Psychosom 67:168-72. 1998
    ..A multidisciplinary team approach to the treatment of pituitary tumors will allow for the early diagnosis of neurobehavioral disorders and the institution of pharmacologic and behavioral interventions...
  29. ncbi Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients
    A D Valentine
    Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:1694-8. 2001
    ..Consideration of cognitive dysfunction and depression complicates the understanding of cancer-related fatigue; however, it provides opportunities to assist patients who must deal with this serious problem...
  30. ncbi Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy
    Jared F Benge
    Mental Health Care Line, Michael E DeBakey Veteran s Affairs Medical Center, Houston, Texas 77230 1402, USA
    J Int Neuropsychol Soc 15:1002-11. 2009
    ..The need for longer-term follow-up studies and increasing utilization of neuropsychological assessments in this population are discussed...
  31. ncbi Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy
    Bouthaina S Dabaja
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 98:1021-8. 2003
    ..CONCLUSIONS: Hyperfractionated WBRT with concurrent BUdR after chemotherapy was found to result in modest disease control but has unacceptable neurotoxicity...
  32. ncbi Neuropsychological effects of third ventricle tumor surgery
    Melissa A Friedman
    The Brain and Spine Center, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Neurosurgery 52:791-8; discussion 798. 2003
    ..In the current study, different types of treatment were not associated with differential cognitive sequelae, and surgical intervention did not account for cognitive deficits...
  33. ncbi Neurochemical basis of interleukin 2-modified discrimination behaviour
    B T Ho
    Department of Neuro Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030
    Cytokine 6:365-7. 1994
    ..Data from the present study show that IL-2 exerts the same neurochemical action as that previously observed with IFN-alpha for both d-amphetamine and EKC discrimination in rats...
  34. ncbi Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:1974-8. 2007
    ....
  35. ncbi Pretreatment cognitive performance predicts survival in patients with leptomeningeal disease
    Audrey M Sherman
    Department of Neuro-Oncology, M. D. Anderson Cancer Center, Houston 77030, USA
    Cancer 95:1311-6. 2002
    ..CONCLUSIONS: Neuropsychological assessment appears to be a valuable tool both for tracking disease course over time and for predicting survival of patients...
  36. ncbi A cytokine-based neuroimmunologic mechanism of cancer-related symptoms
    Bang-Ning Lee
    Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Neuroimmunomodulation 11:279-92. 2004
    ..These concepts open exciting new avenues for translational research in the pathophysiology and treatment of cancer-related symptoms...
  37. ncbi Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy
    Randall S Scheibel
    Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX, USA
    J Neuropsychiatry Clin Neurosci 16:185-91. 2004
    ..There was some evidence suggesting that exposure to chemotherapy and higher cumulative IFN-alpha dose may contribute to cognitive impairment...
  38. ncbi Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism
    Elizabeth A Mittendorf
    Department of Surgical Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Endocr Pract 13:338-44. 2007
    ..To investigate the frequency of the nontraditional symptoms of sleep disturbance and impaired cognitive functioning in patients with primary hyper-parathyroidism (PHPT) and to assess changes in such patients after parathyroidectomy...
  39. ncbi Neurobehavioral effects of interferon therapy
    Alan D Valentine
    U.T. M. D. Anderson Cancer Center, Department of Neuro-Oncology, Unit 431, P.O. Box 301402, Houston, TX 77230, USA
    Curr Psychiatry Rep 7:391-5. 2005
    ..Antipsychotic and psychostimulant drugs may be used against cognitive dysfunction. Antidepressants have been shown to be effective against IFN-induced depression and can be very valuable in support of adequate or completed therapy...
  40. ncbi Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points
    Minesh P Mehta
    Department of Human Oncology, Medical School, University of Wisconsin Madison, K4 334 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    J Clin Oncol 20:3445-53. 2002
    ....
  41. ncbi Neuropsychological and emotional challenges in a 38-year-old man with a brain tumor
    Mark Itzen
    Department of Social Work, Fox Chase Cancer Center, Philadelphia, Pennsylvannia, USA
    Cancer Pract 10:266-8. 2002
  42. ncbi Association of cancer-related symptoms with physiological parameters
    Christina A Meyers
    J Pain Symptom Manage 24:359-61. 2002
  43. ncbi Neurocognitive and functional assessment of patients with brain metastases: a pilot study
    Mary A Herman
    Department of Human Oncology, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA
    Am J Clin Oncol 26:273-9. 2003
    ..Despite high functional status, most patients demonstrated impairment in memory and fine motor domains. Neurocognitive test batteries can and should be used in patients with brain metastases enrolled in clinical trials...
  44. ncbi Cancer as a risk factor for dementia: a house built on shifting sand
    Jeffrey S Wefel
    J Natl Cancer Inst 97:788-9. 2005
  45. ncbi The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity
    Christina A Meyers
    J Clin Oncol 21:3557-8. 2003
  46. ncbi Depression in patients with high-grade glioma: results of the Glioma Outcomes Project
    N Scott Litofsky
    Division of Neurosurgery, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Neurosurgery 54:358-66; discussion 366-7. 2004
    ..To study the incidence of depression among patients undergoing surgery for high-grade glioma, document factors associated with the presence of depression, and examine the relationship between depression and patient outcome...